FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216536698> ?p ?o ?g. }

• W3216536698 abstract "Rationale: SARS-CoV-2 gains entrance to airway epithelial cells (AECs) through binding of the viral spike protein to the angiotensin-converting enzyme 2 (ACE2) on the cell surface. However, ACE2 also converts angiotensin II into angiotensin-(1-7) and counterbalances the renin-angiotensin-aldosterone system, with resultant protective effects in the cardiovascular system. Some data suggest that two common antihypertension medications (angiotensin II receptor antagonists, ARBs; and angiotensin-converting-enzyme inhibitors, ACEIs) may increase ACE2 expression in heart and kidney cells, fueling debate about how these widely used medications may modulate SARS-CoV-2 infectivity and risk of COVID-19. Aim: Determine whether exposure of bronchial AECs to the ARB losartan or the ACEI captopril modulate expression of ACE2 by AECs, SARS CoV2 replication, or expression of proinflammatory cytokines and type I and III interferon (IFN) responses. Methods: Primary bronchial AECs from children and adults ( n = 19; Ages 8–75 yrs) were differentiated ex vivo at an air-liquid interface to generate organotypic cultures. Cultures were treated with captopril (1 μM) or losartan (2 μM) with culture media changes starting 72 h before infection with SARS-CoV-2. In a biosafety level 3 (BSL-3) facility, cultures were infected with SARS-CoV-2 isolate USA-WA1/2020 at a multiplicity of infection (MOI) of 0.5. At 96 h following infection, RNA and protein were isolated. SARS-CoV-2 replication in cultures was assessed with quantitative PCR (qPCR). ACE2, IL-6, IL-1B, IFNB1 , and IFNL2 expression were assessed by qPCR. Results: Neither captopril nor losartan treatment significantly changed ACE2, IL-6, IL-1B, IFNB1 , or IFNL2 expression by AECs as compared to SARS-CoV-2 infected AEC cultures without captopril or losartan treatment. At 96 h following infection, SARS-CoV-2 copy number/ng RNA was not significantly different between untreated AEC cultures, cultures treated with captopril, or cultures treated with losartan. Conclusion: These findings suggest that at the level of the airway epithelium neither the ACEI captopril or ARB losartan significantly modify expression of the SARS-CoV-2 entry factor ACE2, nor does either medication increase replication SARS-CoV-2 replication. This ex vivo data is reassuring and is consistent with evolving clinical data suggesting ACEIs and ARBs do not increase the risk for poor prognosis with COVID-19 and may actually reduce the risk of COVID-19 disease." @default.
• W3216536698 created "2021-12-06" @default.
• W3216536698 creator A5024851562 @default.
• W3216536698 creator A5031922617 @default.
• W3216536698 creator A5034645376 @default.
• W3216536698 creator A5049943255 @default.
• W3216536698 creator A5052547029 @default.
• W3216536698 creator A5066038030 @default.
• W3216536698 creator A5070427565 @default.
• W3216536698 creator A5086923719 @default.
• W3216536698 date "2021-11-19" @default.
• W3216536698 modified "2023-10-03" @default.
• W3216536698 title "Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial Cells" @default.
• W3216536698 cites W1524851323 @default.
• W3216536698 cites W1964982019 @default.
• W3216536698 cites W1984066690 @default.
• W3216536698 cites W1989215732 @default.
• W3216536698 cites W2003835480 @default.
• W3216536698 cites W2008763832 @default.
• W3216536698 cites W2014059528 @default.
• W3216536698 cites W2028521865 @default.
• W3216536698 cites W2043551932 @default.
• W3216536698 cites W2050539440 @default.
• W3216536698 cites W2060204625 @default.
• W3216536698 cites W2083695720 @default.
• W3216536698 cites W2089254530 @default.
• W3216536698 cites W2091671824 @default.
• W3216536698 cites W2104620139 @default.
• W3216536698 cites W2108244474 @default.
• W3216536698 cites W2110926887 @default.
• W3216536698 cites W2143892469 @default.
• W3216536698 cites W2145181045 @default.
• W3216536698 cites W2159560438 @default.
• W3216536698 cites W2276456304 @default.
• W3216536698 cites W2406936899 @default.
• W3216536698 cites W2766895890 @default.
• W3216536698 cites W2807776209 @default.
• W3216536698 cites W3008827533 @default.
• W3216536698 cites W3009799538 @default.
• W3216536698 cites W3009912996 @default.
• W3216536698 cites W3011134208 @default.
• W3216536698 cites W3012184818 @default.
• W3216536698 cites W3012405893 @default.
• W3216536698 cites W3016944852 @default.
• W3216536698 cites W3020655115 @default.
• W3216536698 cites W3025160648 @default.
• W3216536698 cites W3030537287 @default.
• W3216536698 cites W3033263367 @default.
• W3216536698 cites W3034738476 @default.
• W3216536698 cites W3043029189 @default.
• W3216536698 cites W3045552416 @default.
• W3216536698 cites W3048867192 @default.
• W3216536698 cites W3081075404 @default.
• W3216536698 cites W3087591774 @default.
• W3216536698 cites W3105445495 @default.
• W3216536698 cites W3133772724 @default.
• W3216536698 cites W3134173365 @default.
• W3216536698 cites W3154092881 @default.
• W3216536698 cites W3156505617 @default.
• W3216536698 cites W3159875380 @default.
• W3216536698 cites W3182774911 @default.
• W3216536698 cites W3189374950 @default.
• W3216536698 cites W3189622800 @default.
• W3216536698 doi "https://doi.org/10.3389/fphar.2021.765951" @default.
• W3216536698 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34867390" @default.
• W3216536698 hasPublicationYear "2021" @default.
• W3216536698 type Work @default.
• W3216536698 sameAs 3216536698 @default.
• W3216536698 citedByCount "4" @default.
• W3216536698 countsByYear W32165366982022 @default.
• W3216536698 countsByYear W32165366982023 @default.
• W3216536698 crossrefType "journal-article" @default.
• W3216536698 hasAuthorship W3216536698A5024851562 @default.
• W3216536698 hasAuthorship W3216536698A5031922617 @default.
• W3216536698 hasAuthorship W3216536698A5034645376 @default.
• W3216536698 hasAuthorship W3216536698A5049943255 @default.
• W3216536698 hasAuthorship W3216536698A5052547029 @default.
• W3216536698 hasAuthorship W3216536698A5066038030 @default.
• W3216536698 hasAuthorship W3216536698A5070427565 @default.
• W3216536698 hasAuthorship W3216536698A5086923719 @default.
• W3216536698 hasBestOaLocation W32165366981 @default.
• W3216536698 hasConcept C126322002 @default.
• W3216536698 hasConcept C134018914 @default.
• W3216536698 hasConcept C140704245 @default.
• W3216536698 hasConcept C159047783 @default.
• W3216536698 hasConcept C170493617 @default.
• W3216536698 hasConcept C198710026 @default.
• W3216536698 hasConcept C203014093 @default.
• W3216536698 hasConcept C2522874641 @default.
• W3216536698 hasConcept C27016395 @default.
• W3216536698 hasConcept C2775946041 @default.
• W3216536698 hasConcept C2779134260 @default.
• W3216536698 hasConcept C2779479957 @default.
• W3216536698 hasConcept C2780288358 @default.
• W3216536698 hasConcept C2908929049 @default.
• W3216536698 hasConcept C3008058167 @default.
• W3216536698 hasConcept C524204448 @default.
• W3216536698 hasConcept C71924100 @default.
• W3216536698 hasConcept C84393581 @default.
• W3216536698 hasConcept C98274493 @default.

• next